FY26 Interim Results to 30 June 2026

Fevertree delivered solid H1 FY26 growth with rising revenue, EPS, and dividend.

What the company is saying

Fevertree highlights 8% brand revenue growth at constant currency for H1 FY26, emphasizing strategic progress and strong performance across all regions. The company frames its US momentum as a direct result of the Molson Coors partnership and its first national US marketing campaign, describing this as a 'significant step-up in investment.' UK growth is attributed to Off-Trade strength, market share gains, and the 'Straight up or Mixed' campaign, with Ginger Beer and Mexican Lime Soda singled out for sales growth. CEO Tim Warrillow asserts confidence in meeting full-year expectations, citing the business's cash generative model and ability to invest in growth while returning capital to shareholders. The narrative stresses diversification, noting products beyond Tonic now make up 47% of group sales, up from 39% three years ago. The company claims to be well hedged on input costs and maintains unchanged FY26 guidance, but does not quantify the hedging impact.

What the data suggests

The numbers confirm a positive financial trajectory: total adjusted revenue rose 7% year-on-year to £184.2 million, with brand revenue up 8% at constant currency. US revenue increased 11% at constant currency to £66.9 million, while UK revenue grew 3% to £49.5 million and Europe saw 10% constant currency growth to £49.6 million. Rest of World revenue increased 5% at constant currency to £17.6 million, with Australia, New Zealand, and Canada all achieving double-digit underlying growth. Adjusted EBITDA climbed 9% to £20.1 million, and the margin improved to 10.9% from 10.7%. Diluted EPS jumped 38% to 9.44p, while normalised EPS rose 5% to 11.00p. The interim dividend increased 2% to 6.09p per share. The company is executing a £60 million share buyback after completing a £100 million programme in FY25, supported by a £68 million cash position. Product diversification is evident: products beyond Tonic now represent 47% of group sales, up from 39% three years ago, and in the UK, beyond Tonic products are 32% of sales versus 24% three years ago. Ginger Beer gained 2.5% value share in Europe and contributed to over 50% of the Ginger Beer category growth at European retail. The company claims to be well hedged on glass and aluminum costs but provides no quantification. Overall, the disclosed figures support management's claims of growth and diversification, though some operational assertions (hedging, marketing ROI) remain unquantified.

Analysis

The announcement's tone is positive but largely proportionate to the disclosed financial results. The majority of key claims are realised and supported by concrete figures: revenue, EBITDA, EPS, dividend, and cash are all disclosed with year-on-year growth. Only a small fraction of claims are forward-looking, such as hedging effectiveness and unchanged FY26 expectations, and these are presented as status updates rather than aspirational projections. There is no evidence of narrative inflation or exaggerated language relative to the actual progress; the release avoids grandiose claims and focuses on realised operational and financial improvements. The capital outlays (notably the share buyback) are already underway or completed, with no indication of long-dated, uncertain returns. The gap between narrative and evidence is minimal, with only minor unquantified statements regarding marketing investment and hedging.

Risk flags

• ●Cash reserves have declined from £130 million in H1 FY25 to £68 million in H1 FY26, reflecting significant capital returns and investment. While the company remains cash generative, this reduction limits flexibility if market conditions deteriorate or input costs rise unexpectedly.
• ●The effectiveness of the company's hedging on glass and aluminum costs is asserted but not quantified. If hedges are insufficient or expire before cost pressures abate, margin improvement could stall or reverse.
• ●US segment adjusted EBITDA margin fell from 8.1% to 6.2% despite revenue growth, reflecting increased marketing investment. If this investment does not translate into sustained sales or margin gains, US profitability may lag expectations.
• ●The ongoing £60 million share buyback and recent £100 million return to shareholders increase financial leverage and reduce cash, raising the risk if future earnings or cash flow underperform.
• ●Operational momentum in the UK Off-Trade and Europe is partly attributed to favourable weather and order phasing, which may not recur in H2, potentially tempering growth rates.

Bottom line

Fevertree's H1 FY26 results show broad-based revenue growth, improved EBITDA, and higher EPS, with the company delivering on its diversification strategy and maintaining its market leadership in core categories. The US partnership with Molson Coors is driving double-digit revenue growth, but profitability in that segment has dipped due to heavy marketing spend. Cash reserves have halved year-on-year, reflecting aggressive capital returns and investment, but the balance sheet remains strong enough to support ongoing buybacks and dividends. Management's confidence in meeting full-year expectations is credible given the realised H1 performance, though some operational claims (hedging effectiveness, marketing ROI) lack quantification. Investors should watch for margin recovery in the US, cash flow trends, and whether product diversification continues to drive growth in H2. The most important takeaway is that Fevertree is delivering tangible financial progress, but future upside depends on converting marketing and diversification investments into sustained profitability.

Announcement summary

(LSE:FEVR) Fevertree Drinks plc reported FY26 interim results to 30 June 2026, highlighting strong brand revenue growth of 8% at constant currency and continued strategic progress. US revenue increased by 11% at constant currency to £66.9 million, driven by momentum under the Molson Coors partnership and the launch of Fever-Tree's first national US marketing campaign. UK revenue rose 3% to £49.5 million, with a return to growth supported by strong Off-Trade performance, market share gains, and the “Straight up or Mixed” marketing campaign. Europe saw Fever-Tree brand revenue increase by 10% at constant currency to £49.6 million, with strong performances in France and Switzerland. Rest of World revenue grew 5% at constant currency to £17.6 million, with Australia, New Zealand, and Canada all achieving double-digit underlying growth. Adjusted EBITDA increased 9% to £20.1 million, with an adjusted EBITDA margin of 10.9%. Diluted EPS rose 38% to 9.44 pence per share, and normalised EPS increased 5% to 11.00 pence per share. The Board declared an interim dividend of 6.09 pence per share, up 2% year-on-year. A £60 million share buyback programme is underway in 2026, following the £100 million programme completed in FY25, supported by a £68 million cash position. Products beyond Tonic now represent 47% of Group sales, up from 39% three years ago, with Ginger Beer, Pink Grapefruit, and Mexican Lime Soda leading growth. The Group remains well hedged on glass and aluminum costs and maintains unchanged expectations for FY26. A live audio webcast of the results will be held on Thursday 10 September 2026 at 10:00am BST.

Disagree with this article?